Hydralazine 50mg Extended-Release Tablets from Canada
Extended-release tablets providing 50mg hydralazine for once-daily dosing in managing chronic hypertension. Falls under HTS 3004.90.92.20 as a mixed product in measured doses for therapeutic cardiovascular use, put up for retail sale.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Verify extended-release mechanism compliance with FDA dissolution testing standards
• Provide detailed formulation specs including excipients to avoid reclassification as bulk chemical